Related Experiment Video
Updated: Nov 6, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors
Mahmoud Hamed1, Mahmoud El-Hasab2, Fotouh R Mansour1,3
1Pharmaceutical Services Center, Faculty of Pharmacy, Tanta University, Tanta, 31111 Egypt.
Abstract:
The coronavirus pandemic could be the most threatening outbreak in the twenty-first century. According to the latest records of world health organization, more than 130 millions have been infected by COVID-19, with more than 2.9 million reported deaths. Yet, there is no magic cure for treatment of COVID-19. The concept of drug repurposing has been introduced as a fast, life-saving approach for drug discovery. Drug repurposing infers investigating already approved drugs for new indications, using the available information about pathophysiology of diseases and pharmacodynamics of drugs. In a recent work, more than 3000 FDA approved drugs were tested using virtual screening as potential antiviral agents for COVID-19. In this work, the top ranked five hits from the previous docking results together with drugs of similar chemical feature and/or mechanistic destinations were further tested using AutoDock Vina. The results showed that anti-HCV combinations could be potential therapeutic regimens for COVID-19 infections.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s13337-021-00691-6.
Insights
Drug repurposing offers a promising strategy for combating COVID-19. Anti-hepatitis C virus (HCV) drug combinations show potential as effective therapeutic regimens for coronavirus infections.
Area of Science:
- Virology
- Drug Discovery
- Computational Chemistry
Background:
- The COVID-19 pandemic presents a significant global health threat.
- Over 130 million infections and 2.9 million deaths have been reported worldwide.
- No definitive cure for COVID-19 currently exists.
Purpose of the Study:
- To identify potential therapeutic agents for COVID-19 through drug repurposing.
- To evaluate approved drugs as novel treatments for coronavirus infections.
- To explore anti-HCV drug combinations as potential COVID-19 therapies.
Main Methods:
- Virtual screening of over 3000 FDA-approved drugs against COVID-19 targets.
- Further testing of top-ranked drug candidates using AutoDock Vina.
- Analysis of drugs with similar chemical structures and mechanistic pathways.
Main Results:
- Identified potential antiviral agents for COVID-19 from existing drug libraries.
- Top-ranked compounds from virtual screening were further validated.
- Anti-HCV drug combinations demonstrated efficacy in computational models.
Conclusions:
- Drug repurposing is a viable and rapid approach for discovering COVID-19 treatments.
- Anti-HCV drug combinations represent a promising therapeutic strategy for COVID-19.
- Further clinical investigation of these repurposed drugs is warranted.
Related Concept Videos
Subviral Agents
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Viruses with RNA Genomes

